Randomized controlled trial on immunomodulatory Effects of Azithromycin in Children with Steroid Dependent Nephrotic Syndrome

Randomized controlled trial on immunomodulatory Effects of Azithromycin in Children with Steroid Dependent Nephrotic Syndrome - Immunomodulatory effect of azithromycin on SDNS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035961

Enrollment

Registered

2019-02-26

Start date

2018-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

complteted

Interventions

Azithromycin 10mg/kg/d for 3 days and the course was repeated over 5 months + prednisone 1.5 mg/kg every other day for 1 month then 1 mg/kg every other day for 2 months then 0.5 mg/kg every other day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with idiopathic steroid dependent nephrotic syndrome (SDNS) in relapse

Exclusion criteria

Exclusion criteria: - Patients have received immunosuppressive or cytotoxic drugs other than steroids. - Patients with impaired liver functions, or with baseline risk of cardiovascular disease (i.e. prolonged QT syndrome, abnormally slow heart rate, congenital or acquired cardiac diseases or low levels of potassium and magnesium) - Secondary nephrotic syndrome

Design outcomes

Primary

Measure	Time frame
Comparison of TNF in both studied groups at different points throughout the study period.	—

Secondary

Measure	Time frame
- Reported significant persistent adverse effects of AZM - Poor compliance of the patients - Occurrence of relapse	—

Countries

Africa

Contacts

Public ContactHeba Mostafa

Beni Suef University Pediatric Nephrology

heba_most@yahoo.com+201001516641

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026